May 16, 2025

FDA Clears First Blood Test for Alzheimer’s

The FDA has cleared the first blood-based test to aid in diagnosing Alzheimer’s disease, offering a less invasive alternative to positron emission tomography scans and cerebrospinal fluid testing for cognitively impaired patients.

Conexiant

May 16, 2025

FDA Approves PD-1–Targeted Monoclonal Antibody for SCAC

The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.

Conexiant

May 16, 2025

Delandistrogene Moxeparvovec: Efficacy Evidence Questioned

The AAN Guidelines Subcommittee review finds delandistrogene moxeparvovec for DMD failed to meet primary functional outcomes despite FDA approval.

Conexiant

May 15, 2025

Assistant Professor Salary Gaps Persist Nationwide

Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.

Conexiant

May 14, 2025

Leading Cause of Death in Residents, Study

Study shows high suicide rates during training transitions, with pathology residents facing the highest suicide risk compared with other specialties.

Conexiant

May 09, 2025

BAL Guides Treatment in Pediatric Respiratory Illness

BAL detected pathogens in 61% of cases and led to treatment changes in nearly 9 out of 10 immunocompromised children with acute respiratory illness, according to a new 5-year study.

Conexiant

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

April 30, 2025

Is That IPA PFAS-Free?

“Approximately 18% of U.S. breweries are located within zip codes with detectable Per- and polyfluoroalkyl substances (PFAS) in drinking water."

Conexiant

April 30, 2025

New Phase III Data on Brensocatib Therapy

Phase III trial results show that once-daily brensocatib reduces pulmonary exacerbations and slows lung function decline in patients with bronchiectasis.

Conexiant